Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | TTR | P02766 | 3/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19642440 | 0.85 | MAOB (0.46) | MAOBELANEADORA1PRKDC | |
| SCHEMBL29547657 | 0.85 | MAOB (0.46) | MAOBELANEADORA1PRKDC | |
| SCHEMBL19642379 | 0.73 | TTR (0.56) | TTR | |
| SCHEMBL8815383 | 0.71 | TTR (0.65) | TTR | |
| SCHEMBL29548320 | 0.66 | CYP1A1 (0.36) | TTRELANEPRKDC | |
| SCHEMBL19642363 | 0.66 | CYP1A1 (0.36) | TTRELANEPRKDC | |
| SCHEMBL14693731 | 0.64 | MAOB (0.97) | MAOBCNR2 | |
| SCHEMBL31193433 | 0.64 | MAOA (0.64) | TTR | |
| SCHEMBL19642391 | 0.64 | TTR (0.50) | TTRPRKDC | |
| SCHEMBL6570481 | 0.64 | MAOA (0.64) | TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | claimed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | claimed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | claimed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2017202798-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611748-B2 | Xanthone derivatives for the treatment of hepatitis B virus disease | XDH, XPOT, HAVCR2 | MAOB 257/4885TTR 1892/4885ELANE 530/4885 |
| US-20190185444-A1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | XDH, HAVCR2, XPA | MAOB 242/4885TTR 1316/4885ELANE 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.